<DOC>
	<DOC>NCT02738775</DOC>
	<brief_summary>This study evaluates the use of single agent ublituximab, a novel monoclonal antibody, in patients with relapsing forms of multiple sclerosis</brief_summary>
	<brief_title>Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Diagnosis of relapsed multiple sclerosis Active disease Greater than 1 relapse in prior 2 years Treatment with antiCD20 monoclonal antibody within the last 12 months Treatment with alemtuzumab within the last 12 months Pregnant or nursing mothers</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>multiple sclerosis</keyword>
</DOC>